Fig. 3. eGFR slope estimates over time of people with renal cancer treated with VEGF-signalling pathway inhibitors and/or immune checkpoint inhibitors using the linear mixed-effects model from the point of systemic therapy to 2 years from follow-up.

Demonstrated as the average eGFR change of the of the group, and specifically for people who had nephrectomy prior to systemic therapy, metastatic cancer at the point of diagnosis and an average eGFR <60 ml/min/1.73m² before systemic therapy.